Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2022 Jan 23;89(2):231–242. doi: 10.1007/s00280-021-04388-x

Table 1.

Noncompartmental AZD6738 PK parameters

Route Dose (mg/kg) IV 10 PO 2.0 PO 7.5 PO 20 PO 75 p-valueb PO-extf 75
Actual dose (mg/kg) 11.7 1.92 8.8 23.4 90.5 88.4

Cmax (μg/mL) 7.04 (0.93) 0.160 (0.069) 1.46 (0.26) 4.96 (1.50) 12.0 (1.0) 14.1 (1.7)
Cmax/dosea 0.604 (0.093) 0.0829 (0.034) 0.172 (0.035) 0.212 (0.075) 0.133 (0.013) 0.0395 0.160 (0.019)
Tmax (min) 5 60 15 15 15 15
AUC0-360 (μg/mL•min) 330 (17) 22.8 (3.3) 130 (18) 545 (81) 2,241 (135) 0.0002 2,371 (185)
AUC0-360/dosea,c 28.3 (1.5) 11.8 (1.7) 15.4 (2.1) 23.3 (3.5) 24.8 (1.5) 26.8 (2.1)
AUC0-∞ (μg/mL•min) 337 25.4 144 578 2,495 2,371 (185)
AUC0-∞ /dosea 28.9 13.2 17.0 24.7 27.6 0.0002 26.8 (2.1)
Fd - 0.457 0.588 0.855 0.952
CI (mL/min/kg)e 34.5 75.7 58.8 40.4 36.3 37.3
Vd (L/kg)e 4.92 11.4 11.0 5.50 6.06 5.66
Half-life (min) 98.6 104 130 94.4 116 105
0-24h urine (% dose) 1.91 2.51 3.07 3.61 3.06     3.19
CIR (mL/min/kg) 0.661 1.97 1.88 1.53 1.14     1.19
0-24h feces (% dose) 13.9 15.7 13.5 16.1 9.22     8.58

Values represent the mean and error (SD for Cmax, SEM for AUC)

a:

calculated using exact dose

b:

ANOVA test of PO routes only

c:

% extrapolated ranges from 0.008 to 10.4%

d:

Based on AUC0-∞

e:

Apparent parameter for initial 4 PO doses 2, 7.5, 20, and 75 mg/kg

f:

Plasma PK parameters for the tissue distribution study